甲泼尼龙联合甲氨蝶呤方案对比泼尼松标准治疗用于巨细胞动脉炎:倾向性评分研究
在西班牙三家学术医院开展的真实临床实践研究,纳入151例新诊断巨细胞动脉炎患者,比较泼尼松标准治疗(40-60 mg/d)与静脉甲泼尼龙冲击后低剂量泼尼松(≤30 mg/d)联合甲氨蝶呤方案的疗效与安全性,随访2年。倾向性评分校正后显示两种方案缓解率与复发率相似,联合方案显著降低累积糖皮质激素剂量及激素相关不良事件。
要点
- 联合方案组泼尼松减至≤5 mg/d更快(平均13.8 vs 56.5周,P<0.001)
- 联合方案组激素相关不良事件调整OR 0.35(95%CI 0.14-0.85,P=0.021)
核心结论
- 静脉甲泼尼龙联合甲氨蝶呤与低剂量泼尼松方案在诱导缓解和预防复发方面与标准治疗同样有效。
- 该联合方案显著减少糖皮质激素暴露及激素相关不良事件。
- 静脉甲泼尼龙联合甲氨蝶呤可能是潜在的激素节约策略,尤其适用于激素毒性风险较高的巨细胞动脉炎患者。
研究设计与样本
- 在西班牙三家学术医院开展的真实临床实践研究,纳入151例新诊断巨细胞动脉炎患者。
- 标准治疗组接受泼尼松40-60 mg/d;联合方案组接受静脉甲泼尼龙125-500 mg/d×3天,继以泼尼松≤30 mg/d联合甲氨蝶呤,随访2年。
- 采用倾向性评分在多变量分析中校正基线差异。
主要发现
- 79例(52.3%)接受标准治疗泼尼松,72例(47.7%)接受静脉甲泼尼龙联合甲氨蝶呤方案。
- 两组基线临床特征相似。
- 全部患者均达到缓解,中位缓解时间4周,组间无差异。
- 两组复发率相似。
- 联合方案组累积糖皮质激素剂量显著低于标准治疗组,且达到泼尼松≤5 mg/d更快(平均13.8 vs 56.5周;P < 0.001)。
关键数值与推荐
- 标准治疗组泼尼松剂量40-60 mg/d。
- 联合方案组静脉甲泼尼龙125-500 mg/d×3天,继以泼尼松≤30 mg/d联合甲氨蝶呤。
- 达到泼尼松≤5 mg/d的时间:联合方案组平均13.8周 vs 标准治疗组平均56.5周(P < 0.001)。
- 激素相关不良事件:调整OR 0.35(95%CI 0.14-0.85;P = 0.021)。
临床怎么用
- 原文未据此给出推荐,作者认为静脉甲泼尼龙联合甲氨蝶呤可能是潜在的激素节约策略,尤其适用于激素毒性风险较高的巨细胞动脉炎患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Treatment of GCA still requires substantial exposure to glucocorticoids (GCs), which are associated with significant toxicity. This study compares the efficacy and safety of the GC-only standard of care (SOC) with a regimen combining intravenous methylprednisolone (IVMP) pulses, MTX and lower doses of prednisone, in newly diagnosed patients with GCA. METHODS: A usual clinical practice study was conducted in three Spanish academic hospitals. One hundred and fifty-one patients diagnosed with GCA were treated with SOC prednisone (40-60 mg/d) or with IVMP (125-500 mg/d ×3) followed by lower-dose prednisone (≤30 mg/d) and MTX (IVMP/MTX), with a follow-up of 2 years. A propensity score was used to adjust for baseline differences in the multivariate analyses. RESULTS: Seventy-nine (52.3%) patients received SOC prednisone and 72 (47.7%) IVMP/MTX. The clinical characteristics at baseline were similar in both the groups. Hundred percent patients achieved remission after a median time of 4 weeks, without differences between the groups. Relapse rates were also similar. Patients receiving IVMP/MTX had significantly lower cumulative GC doses and reached prednisone ≤5 mg/d faster than SOC patients (mean 13.8 vs 56.5 weeks; P < 0.001). Patients in the IVMP/MTX group were less likely to suffer any GC-related adverse effect (adjusted OR 0.35, 95% CI 0.14-0.85; P = 0.021). CONCLUSIONS: The combination IVMP/MTX with lower-dose prednisone is as effective as the SOC in inducing remission and preventing relapses in GCA. The IVMP/MTX scheme significantly reduces GC exposure and GC-associated adverse effects. IVMP/MTX could be a potential GC-sparing strategy, especially in patients with GCA at higher risk of GC toxicity.
引用
- Soto-Peleteiro A, Hernández-Rodríguez J, Raad F, et al. Methylprednisolone plus MTX-based regime vs prednisone-based standard of care for GCA: a propensity score study. Rheumatology (Oxford). 2026. PMID: 40971971. doi:10.1093/rheumatology/keaf499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。